Herpes Zoster Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major herpes zoster markets are expected to exhibit a CAGR of 2.61% during 2024-2034.
The herpes zoster market has been comprehensively analyzed in IMARC's new report titled "Herpes Zoster Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Herpes zoster, also known as shingles, is a type of viral infection that damages the skin and nerves. This condition typically manifests as a painful rash that appears in a localized area of the body, particularly on one side of the torso. Individuals suffering from the ailment may also experience itching, tingling, and burning sensations, as well as general flu-like symptoms, including fever, headache, fatigue, etc. In most cases, the rash develops into small, fluid-filled blisters, which eventually begin to dry out and crust over. The diagnosis of herpes zoster involves a medical evaluation based on the patient's indications and physical examination. Several blood workups, such as enzyme-linked immunosorbent assay (ELISA) and immunofluorescence assays, are also performed to measure the levels of antibodies that are specific to the varicella-zoster virus in the blood. Additionally, the healthcare professional may conduct a Tzanck smear analysis by obtaining a sample from a skin blister and examining it under a microscope to check for the presence of abnormal multinucleated giant cells indicative of the condition.
The increasing cases of chickenpox infection, in which the virus does not entirely leave the body and instead retreats to sensory nerve cells, are primarily driving the herpes zoster market. In addition to this, the expanding geriatric population, who are more prone to physical and emotional stress that can disrupt the immune system and potentially trigger viral reactivation, is creating a positive outlook for the market. Moreover, the widespread adoption of recombinant zoster vaccine owing to its various advantages, like long-lasting protection, enhanced efficacy, and minimal side effects, is further bolstering the market growth. Apart from this, the rising usage of topical antiviral creams, such as acyclovir and penciclovir, which can be applied directly on the rash to inhibit the replication of the virus, thereby reducing the severity and duration of the disease, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of polymerase chain reaction (PCR) techniques to aid in early diagnosis by detecting even low levels of viral DNA or RNA in the patient's sample is expected to drive the herpes zoster market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the herpes zoster market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for herpes zoster and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the herpes zoster market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the herpes zoster market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the herpes zoster market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current herpes zoster marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the herpes zoster market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the herpes zoster market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the herpes zoster market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of herpes zoster across the seven major markets?
What is the number of prevalent cases (2018-2034) of herpes zoster by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of herpes zoster by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with herpes zoster across the seven major markets?
What is the size of the herpes zoster patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of herpes zoster?
What will be the growth rate of patients across the seven major markets?
Herpes Zoster: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for herpes zoster drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the herpes zoster market?
What are the key regulatory events related to the herpes zoster market?
What is the structure of clinical trial landscape by status related to the herpes zoster market?
What is the structure of clinical trial landscape by phase related to the herpes zoster market?
What is the structure of clinical trial landscape by route of administration related to the herpes zoster market?
The herpes zoster market has been comprehensively analyzed in IMARC's new report titled "Herpes Zoster Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Herpes zoster, also known as shingles, is a type of viral infection that damages the skin and nerves. This condition typically manifests as a painful rash that appears in a localized area of the body, particularly on one side of the torso. Individuals suffering from the ailment may also experience itching, tingling, and burning sensations, as well as general flu-like symptoms, including fever, headache, fatigue, etc. In most cases, the rash develops into small, fluid-filled blisters, which eventually begin to dry out and crust over. The diagnosis of herpes zoster involves a medical evaluation based on the patient's indications and physical examination. Several blood workups, such as enzyme-linked immunosorbent assay (ELISA) and immunofluorescence assays, are also performed to measure the levels of antibodies that are specific to the varicella-zoster virus in the blood. Additionally, the healthcare professional may conduct a Tzanck smear analysis by obtaining a sample from a skin blister and examining it under a microscope to check for the presence of abnormal multinucleated giant cells indicative of the condition.
The increasing cases of chickenpox infection, in which the virus does not entirely leave the body and instead retreats to sensory nerve cells, are primarily driving the herpes zoster market. In addition to this, the expanding geriatric population, who are more prone to physical and emotional stress that can disrupt the immune system and potentially trigger viral reactivation, is creating a positive outlook for the market. Moreover, the widespread adoption of recombinant zoster vaccine owing to its various advantages, like long-lasting protection, enhanced efficacy, and minimal side effects, is further bolstering the market growth. Apart from this, the rising usage of topical antiviral creams, such as acyclovir and penciclovir, which can be applied directly on the rash to inhibit the replication of the virus, thereby reducing the severity and duration of the disease, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of polymerase chain reaction (PCR) techniques to aid in early diagnosis by detecting even low levels of viral DNA or RNA in the patient's sample is expected to drive the herpes zoster market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the herpes zoster market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for herpes zoster and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the herpes zoster market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the herpes zoster market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the herpes zoster market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current herpes zoster marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the herpes zoster market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the herpes zoster market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the herpes zoster market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of herpes zoster across the seven major markets?
What is the number of prevalent cases (2018-2034) of herpes zoster by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of herpes zoster by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with herpes zoster across the seven major markets?
What is the size of the herpes zoster patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of herpes zoster?
What will be the growth rate of patients across the seven major markets?
Herpes Zoster: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for herpes zoster drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the herpes zoster market?
What are the key regulatory events related to the herpes zoster market?
What is the structure of clinical trial landscape by status related to the herpes zoster market?
What is the structure of clinical trial landscape by phase related to the herpes zoster market?
What is the structure of clinical trial landscape by route of administration related to the herpes zoster market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HERPES ZOSTER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HERPES ZOSTER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HERPES ZOSTER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario 2018-2023)
7.8.2 Epidemiology Forecast 2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 HERPES ZOSTER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HERPES ZOSTER - UNMET NEEDS
10 HERPES ZOSTER - KEY ENDPOINTS OF TREATMENT
11 HERPES ZOSTER - MARKETED PRODUCTS
11.1 List of Herpes Zoster Marketed Drugs Across the Top 7 Markets
11.1.1 Valtrex (Valaciclovir) - GlaxoSmithKline
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Zovirax (Acyclovir) - GlaxoSmithKline
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Famvir (Famciclovir) - Novartis
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Shingrix (Zoster Vaccine Recombinant, Adjuvanted) - GlaxoSmithKline
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HERPES ZOSTER - PIPELINE DRUGS
12.1 List of Herpes Zoster Pipeline Drugs Across the Top 7 Markets
12.1.1 CRV 101 - Curevo Vaccine
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 JCXH 105 - Immorna Biotherapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 mRNA 1468 - Moderna Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 PF-07915234 - Pfizer
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HERPES ZOSTER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HERPES ZOSTER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HERPES ZOSTER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Herpes Zoster - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Herpes Zoster - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Herpes Zoster - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Herpes Zoster - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Herpes Zoster - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Herpes Zoster - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Herpes Zoster - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Herpes Zoster - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Herpes Zoster - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Herpes Zoster - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Herpes Zoster - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Herpes Zoster - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Herpes Zoster - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Herpes Zoster - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Herpes Zoster - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Herpes Zoster - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Herpes Zoster - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Herpes Zoster - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Herpes Zoster - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Herpes Zoster - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Herpes Zoster - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Herpes Zoster - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Herpes Zoster - Access and Reimbursement Overview
16 HERPES ZOSTER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HERPES ZOSTER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HERPES ZOSTER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HERPES ZOSTER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HERPES ZOSTER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HERPES ZOSTER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario 2018-2023)
7.8.2 Epidemiology Forecast 2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 HERPES ZOSTER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HERPES ZOSTER - UNMET NEEDS
10 HERPES ZOSTER - KEY ENDPOINTS OF TREATMENT
11 HERPES ZOSTER - MARKETED PRODUCTS
11.1 List of Herpes Zoster Marketed Drugs Across the Top 7 Markets
11.1.1 Valtrex (Valaciclovir) - GlaxoSmithKline
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Zovirax (Acyclovir) - GlaxoSmithKline
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Famvir (Famciclovir) - Novartis
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Shingrix (Zoster Vaccine Recombinant, Adjuvanted) - GlaxoSmithKline
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HERPES ZOSTER - PIPELINE DRUGS
12.1 List of Herpes Zoster Pipeline Drugs Across the Top 7 Markets
12.1.1 CRV 101 - Curevo Vaccine
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 JCXH 105 - Immorna Biotherapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 mRNA 1468 - Moderna Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 PF-07915234 - Pfizer
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HERPES ZOSTER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HERPES ZOSTER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HERPES ZOSTER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Herpes Zoster - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Herpes Zoster - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Herpes Zoster - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Herpes Zoster - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Herpes Zoster - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Herpes Zoster - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Herpes Zoster - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Herpes Zoster - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Herpes Zoster - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Herpes Zoster - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Herpes Zoster - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Herpes Zoster - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Herpes Zoster - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Herpes Zoster - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Herpes Zoster - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Herpes Zoster - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Herpes Zoster - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Herpes Zoster - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Herpes Zoster - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Herpes Zoster - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Herpes Zoster - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Herpes Zoster - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Herpes Zoster - Access and Reimbursement Overview
16 HERPES ZOSTER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HERPES ZOSTER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HERPES ZOSTER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
